1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Coeur Mining's board declared an inaugural dividend of $0.02 per share, consistent with a semi-annual dividend policy the company announced on March 23, 2026. Stockholders also approved a charter amendment limiting the liability of certain officers and elected nine directors at the May 12, 2026 annual meeting, and the company announced that its chief accounting officer will retire in early 2027.
Dividend of $0.02 per share, payable June 10, 2026; effective record date May 22, 2026 because of an NYSE market holiday on May 25, 2026
Stockholders approved the charter amendment limiting officer liability with 75.39% of votes cast, and 51.46% of outstanding shares at the record date voted for it
Vice President, Corporate Controller and Chief Accounting Officer Kenneth J. Watkinson plans to retire in early 2027 and remains in his role until August 10, 2026
Anne Beckelheimer will become Senior Vice President, Tax, Corporate Controller and Chief Accounting Officer effective August 10, 2026
Nortech Systems reported first quarter 2026 results, with net sales up 12.7% to $30.3 million and a net loss of $34 thousand, or $(0.01) per share, compared with a $1.3 million loss, or $(0.48) per share, a year earlier. Revenue growth and a much smaller loss improve the picture for shareholders, while the company also closed $17.2 million in debt financing and reported a total backlog of $90.8 million.
Net sales were $30.3 million in Q1 2026, up from $26.9 million in Q1 2025.
Net loss narrowed to $34 thousand, or $(0.01) per basic share, from $1.3 million, or $(0.48) per share.
Adjusted EBITDA was $350 thousand, compared with a $(1.0) million loss in Q1 2025.
90-day backlog was $31.5 million as of March 31, 2026, up from $26.7 million a year earlier.
Energous reported first quarter 2026 revenue of approximately $3.1 million, up from $0.3 million a year earlier and 1% above the fourth quarter of 2025, marking its fifth consecutive quarter of revenue growth. The net loss narrowed to $1.7 million, or $0.43 per share, from $3.4 million, or $3.55 per share, a year earlier, and cash and equivalents stood at $36.6 million at March 31, 2026.
Revenue of approximately $3.1 million for the quarter ended March 31, 2026, versus $0.3 million in the same period of 2025
Gross margin of 36%, with gross profit of $1.1 million
GAAP net loss of approximately $1.7 million ($0.43 per share) versus $3.4 million ($3.55 per share) a year earlier
During the quarter the company raised $31.9 million net under its at-the-market program and has not sold shares under it since March 19, 2026
Acadia Realty Trust reported first-quarter 2026 results and raised its full-year 2026 guidance for FFO As Adjusted to $1.22-$1.26 per share from $1.21-$1.25. Net income attributable to Acadia shareholders was $30.5 million, compared with $1.6 million a year earlier, though NAREIT FFO per share fell to $0.26 from $0.34. The company also corrected several figures in the supplemental report and reported that all eight trustee nominees were elected at its May 13 annual meeting.
Q1 2026 FFO As Adjusted per diluted share was $0.30, up from $0.27 in Q1 2025; NAREIT FFO per diluted share was $0.26, down from $0.34.
2026 guidance raised: FFO As Adjusted to $1.22-$1.26 from $1.21-$1.25; net earnings per share to $0.37-$0.39 from $0.24-$0.26.
Net income attributable to Acadia shareholders was $30.5 million, versus $1.6 million, with a $142.1 million consolidated gain on disposition of properties in the quarter.
At the May 13, 2026 annual meeting, all eight trustees were elected and the non-binding advisory vote on executive compensation received 117,956,235 votes for and 6,293,624 against.
The Hanover Insurance Group's board terminated its prior share repurchase program, which had about $63 million remaining, and approved a new authorization of up to $700 million in buybacks with no time limit. The company also named Patricia A. Norton-Gatto as principal accounting officer, replacing CFO Jeffrey M. Farber in that role, and shareholders re-elected eight directors at the May 12, 2026 annual meeting.
New share repurchase authorization of up to $700 million, with no time limit and no obligation to repurchase shares
Prior program, initially approved in December 2018, had about $63 million remaining and was terminated on May 13, 2026
Patricia A. Norton-Gatto, Senior Vice President and Corporate Controller, became principal accounting officer effective May 13, 2026
At the May 12, 2026 annual meeting, all eight directors were elected; Joseph R. Ramrath received 933,965 votes against
Acrivon Therapeutics reported a first-quarter 2026 net loss of $19.0 million, or $0.49 per share, compared with $19.7 million, or $0.51 per share, a year earlier. Lower general and administrative expenses offset flat research and development spending, and the company said its cash is expected to fund operations into the third quarter of 2027.
Net loss for the quarter ended March 31, 2026 was $19.0 million, versus $19.7 million a year earlier; net loss per share was $0.49, versus $0.51.
General and administrative expenses fell to $4.7 million from $6.2 million, mainly due to lower employee-related expenses including stock-based compensation.
Research and development expenses were $15.2 million, versus $15.4 million a year earlier.
Cash, cash equivalents and marketable securities were $97.7 million at March 31, 2026, plus $7.3 million in proceeds from subsequent equity financing.
Cisco reported fiscal third quarter 2026 revenue of $15.8 billion, up 12% year over year, with GAAP net income of $3.4 billion, up 35%, and non-GAAP EPS of $1.06, up 10%. The company also announced a restructuring plan with pre-tax charges of up to $1 billion, mostly cash-based, which shareholders should weigh against the growth figures and the fourth-quarter and full-year guidance.
Q3 fiscal 2026 revenue was $15.8 billion, up 12%; GAAP EPS was $0.85, up 37%; non-GAAP EPS was $1.06, up 10%.
Q4 fiscal 2026 guidance: revenue of $16.7 billion to $16.9 billion and non-GAAP EPS of $1.16 to $1.18.
FY 2026 guidance: revenue of $62.8 billion to $63.0 billion and non-GAAP EPS of $4.27 to $4.29.
Restructuring plan: pre-tax charges of up to $1 billion, with about $450 million expected in Q4 fiscal 2026 and the remainder in fiscal 2027.
Journey Medical reported first-quarter 2026 results for the three months ended March 31, 2026. Total revenue rose 21% to $16.0 million and the net loss narrowed to $2.2 million, or $(0.08) per share, from $4.1 million, or $(0.18) per share, a year earlier. Gross margin fell to 61.0% because of a $1.3 million non-cash inventory write-down tied to a 2021 Qbrexza asset acquisition.
Total revenue was $16.0 million, up from $13.1 million in the first quarter of 2025.
Emrosi revenue was $6.3 million, compared with $2.1 million a year earlier.
Gross margin decreased to 61.0% from 63.5%, mainly due to a $1.3 million non-recurring non-cash charge.
Cash and cash equivalents were $27.2 million at March 31, 2026, up from $24.1 million at December 31, 2025.
STAAR Surgical reported first-quarter 2026 results for the period ended April 3, 2026, with net sales of $93.5 million, up 119.6% from a year earlier, and net income of $5.2 million, or $0.10 per diluted share, compared with a net loss of $54.2 million a year earlier. Net sales excluding China rose 6.0% to $46.1 million, and the company reported no outstanding debt as of April 3, 2026.
Net sales of $93.5 million, up 119.6% from $42.6 million in the first quarter of 2025, primarily reflecting China
Gross margin of 73.6% compared with 65.8% a year earlier
Adjusted EBITDA of $24.4 million, or $0.48 per diluted share, compared with a $26.3 million loss a year earlier
Cash and investments available for sale of $163.9 million at April 3, 2026; net cash used in operating activities was $21.7 million
Spruce Biosciences reported a first-quarter 2026 net loss of $12.3 million, or $(8.94) per share, down from $14.0 million, or $(23.95) per share, a year earlier, as operating expenses fell to $12.0 million from $14.5 million. The company closed a $69.0 million gross underwritten public offering on April 22, 2026, which included 1,150,000 shares, pre-funded warrants and 180,000 option shares, and reported preliminary, unaudited cash of $107.3 million as of April 30, 2026. Shareholders should note that the offering increases the share count, and the company's stated timeline for a BLA submission for TA-ERT is the fourth quarter of 2026.
Net loss of $12.3 million, or $(8.94) per share, for the quarter ended March 31, 2026, versus $14.0 million, or $(23.95) per share, a year earlier.
Total operating expenses of $12.0 million versus $14.5 million; R&D included $5.7 million in one-time product acquisition costs related to SPR202.
Cash and cash equivalents of $54.1 million at March 31, 2026, up from $48.9 million at December 31, 2025.
Closed $69.0 million in aggregate gross offering proceeds on April 22, 2026; preliminary, unaudited cash of $107.3 million as of April 30, 2026.
Vishay Intertechnology reported first-quarter 2026 results for the fiscal quarter ended April 4, 2026, with revenue of $839.2 million, up from $715.2 million in the year-earlier quarter, and GAAP diluted EPS of $0.05 versus a loss of $0.03 a year earlier. The company guided second-quarter 2026 revenue to $875 million to $905 million with a gross margin of 22.0% plus or minus 50 basis points.
Q1 2026 net revenues were $839.2 million, compared with $715.2 million in the quarter ended March 29, 2025, and $800.9 million in the quarter ended December 31, 2025.
Q1 2026 GAAP diluted EPS was $0.05, compared with a loss of $0.03 a year earlier; gross margin was 21.0%.
Q2 2026 outlook: revenues of $875 million to $905 million and a gross profit margin of 22.0% plus or minus 50 basis points.
Q1 2026 book-to-bill was 1.34; backlog at quarter end was 5.7 months. Free cash was negative $46.9 million, against $54.9 million in the prior quarter.
Protalix reported first-quarter 2026 total revenue of $33.8 million, up from $10.1 million a year earlier, and net income of $18.3 million, compared with a net loss of $3.6 million in the prior-year quarter. The increase was driven mainly by a $25.0 million milestone from partner Chiesi, and the company reaffirmed its 2026 total revenue guidance of $78.0 million to $83.0 million, which includes that milestone.
Total revenue was $33.8 million for the quarter ended March 31, 2026, versus $10.1 million a year earlier.
Net income was $18.3 million, or $0.23 per share basic and $0.22 diluted, versus a net loss of $3.6 million, or $(0.05) per share, in Q1 2025.
Revenue from selling goods fell to $7.4 million from $10.0 million, mainly due to a timing shift in Pfizer's Elelyso purchases.
The company reaffirmed 2026 total revenue guidance of $78.0 million to $83.0 million and reported cash and short-term deposits of $51.1 million as of March 31, 2026.
National Vision reported first quarter 2026 results for the period ended April 4, 2026, with net revenue up 6.6% to $543.9 million and net income of $31.2 million, compared with $14.2 million a year earlier. Diluted EPS rose to $0.38 from $0.18, and the company reiterated its fiscal 2026 outlook, including Adjusted Diluted EPS of $0.85 to $1.09.
Net revenue rose 6.6% to $543.9 million; comparable store sales grew 4.4%.
Diluted EPS was $0.38 versus $0.18; Adjusted Diluted EPS was $0.45 versus $0.34.
Fiscal 2026 outlook reiterated: net revenue of $2.033 billion to $2.091 billion and Adjusted Diluted EPS of $0.85 to $1.09.
Expanded relationship with AAFES, effective April 1, 2026, adds 20 Military stores and makes National Vision the sole optical retail partner on U.S. AAFES bases.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.